FLGT News and Press, Fulgent Genetics Inc. From 08/04/22

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent” or the “company”) today announced the addition of two therapeutic industry veterans to its board of directors. Dr. Michael Nohaile, Chief Scientific Officer of Generate Biomedi...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent”, or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today an...

Today, we take a deeper look at Fulgent Genetics, which has benefitted greatly from an explosion of Covid-19 testing revenue. The stock has sold off as fears around the coronavirus have ebbed. However, the company has a huge cash hoard to build up the other parts of its product portfo...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will relea...

Which of the healthcare producers of Diagnostic Solutions is now a better buy to help build your portfolio’s near-term capital value? Near-term only, repetition provides long term. Here find out what the best-informed, big-$ investors now think is likely to happen (good and bad...

The American Medical Association Approves a New Category I CPT® Code for the HelioLiver™ Test PR Newswire The approval of a CPT code establishes a reimbursement pathway for increased access to HelioLiver, a simple blood test to detect hepatocellular carcino...

Greenblatt believes that a company with the ability to invest in its business and receive a strong return on that investment is usually a “good” company. Greenblatt measures the strength of a business by examining its return on capital, which he defines as operating prof...

The company has raked in well over $1B of cash from its epic Covid testing ramp up, apart from a host of contacts and putting the company on the map. It is spending some of that on acquisitions and a massive stock buyback that is yet to commence. However, this is counterbalanced b...

Image source: The Motley Fool. Fulgent Genetics, Inc. (NASDAQ: FLGT) Q1 2022 Earnings Call May 03, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Fulgent Genetics, Inc. (FLGT) Q1 2022 Earnings Call Transcript

Fulgent Genetics, Inc. (FLGT) Q1 2022 Earnings Conference Call May 3, 2022, 04:30 PM ET Company Participants Nicole Borsje - IR Ming Hsieh - CEO Brandon Perthuis - Chief Commercial Officer Larry Weiss - Chief Medical Officer Paul Kim - CFO Conference Call Participants Kevin DeGeeter - Oppenhe...